(NASDAQ: ARCT) Arcturus Therapeutics Holdings's forecast annual revenue growth rate of 62.21% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 49.13%, and it is also forecast to beat the US market's average forecast revenue growth rate of 11.68%.
Arcturus Therapeutics Holdings's revenue in 2025 is $160,399,000.On average, 4 Wall Street analysts forecast ARCT's revenue for 2025 to be $8,175,913,004, with the lowest ARCT revenue forecast at $6,081,112,096, and the highest ARCT revenue forecast at $13,813,198,722. On average, 4 Wall Street analysts forecast ARCT's revenue for 2026 to be $12,456,176,211, with the lowest ARCT revenue forecast at $5,933,756,863, and the highest ARCT revenue forecast at $24,196,054,300.
In 2027, ARCT is forecast to generate $19,024,887,856 in revenue, with the lowest revenue forecast at $7,458,775,174 and the highest revenue forecast at $37,361,052,522.